China’s Yangtze Memory Technologies plans to build two fabs beyond the Phase 3 plant that it’s due to complete in Wuhan this year.

PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins,

Essential3 is the first positive Phase 3 program in essential tremor; ulixacaltamide has received FDA Breakthrough Therapy Designation, with data selected for plenary presentation at AAN 2026Praxis to present 3 oral presentations and 12 posters at AAN 2026Visit Praxis at Booth #2324 for an in-booth speaker showcase featuring Phase 3 Essential3 results for ulixacaltamide,

With the caveat that cross-trial comparisons can be unreliable, zasocitinib appears to have an advantage over Sotyktu. BMS reported PASI 90 rates of 32% to 42% and PASI 100 rates of 10% to 14% in its phase 3 program.

Alkermes announced today the initiation of the Brilliance Studies, a phase 3 program that will test the safety and efficacy of alixorexton compared with placebo in adults, according to a news release. Alixorexton is an investigational treatment for narcolepsy types 1 and 2 and idiopathic hypersomnia (IH).

Zasocitinib showed superiority over placebo in phase 3 trials, achieving rapid and sustained skin clearance in plaque psoriasis. The trials demonstrated a favorable safety profile, with common adverse events including upper respiratory tract infection and acne

Alkermes has reported another phase 2 win for its narcolepsy drug candidate, succeeding where Takeda failed to maintain its hopes of being first to market in the indication. The trial randomized 93 people with narcolepsy type 2 (NT2) to receive one of ...

Hello, and welcome to this market update with the Swedish Diabetes Research Company, Diamyd Medical. On Friday evening, the company announced negative interim results from its Phase III study. We will now discuss what this means with Ulf Hannelius,

The U.S. Space Force has selected SpaceX and United Launch Alliance to perform the first seven launches under the National Security Space Launch Program, or NSSL, Phase 3 Lane 2 contracts, Breaking Defense reported Friday. According to Space Systems ...

Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients,